OR1L1 inhibitors are chemical compounds that specifically target and inhibit the activity of the OR1L1 receptor, which is a member of the olfactory receptor (OR) family. Olfactory receptors, traditionally recognized for their role in odor detection, belong to the large family of G-protein-coupled receptors (GPCRs), which are integral membrane proteins responsible for a wide range of cellular signal transduction processes. OR1L1, like other olfactory receptors, is a seven-transmembrane domain protein, and its inhibition involves modulating the binding of specific ligands that normally activate it. While olfactory receptors are primarily studied in the context of sensory biology, they are increasingly recognized for their broader role in non-olfactory tissues, suggesting that the inhibition of OR1L1 may influence cellular functions beyond odorant recognition.
Structurally, OR1L1 inhibitors are often characterized by their ability to bind to specific sites on the receptor, blocking the conformational changes necessary for signal transduction. The specificity of these inhibitors typically depends on their molecular interaction with the binding pocket of OR1L1, and small modifications in their chemical structure can dramatically affect their binding affinity and inhibitory activity. Inhibitors of this receptor may exhibit diverse chemical frameworks, including heterocyclic compounds, amines, and halogenated aromatics, which contribute to their ability to interact with hydrophobic and polar residues within the receptor. The study of OR1L1 inhibitors from a chemical perspective highlights their potential as valuable tools in dissecting the receptor's broader biochemical and molecular mechanisms, as well as their role in the overall signaling landscape of GPCR systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Blocks beta-adrenergic receptors, can indirectly affect GPCR signaling, including OR1L1's pathway. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A beta-adrenergic agonist, can desensitize GPCRs, leading to a potential decrease in OR1L1 signaling. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-adrenergic antagonist, can affect OR1L1 by modulating the adrenergic signaling pathway. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Selectively blocks beta-1 adrenergic receptors, can influence GPCR signaling pathways affecting OR1L1. | ||||||
Reserpine | 50-55-5 | sc-203370 sc-203370A | 1 g 5 g | $137.00 $414.00 | 1 | |
Depletes monoamine neurotransmitters, can modify GPCR signaling and potentially inhibit OR1L1 function. | ||||||
ZM 241385 | 139180-30-6 | sc-361421 sc-361421A | 5 mg 25 mg | $92.00 $356.00 | 1 | |
An adenosine A2A receptor antagonist, can modify adenosine signaling, which may influence OR1L1 activity. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Blocks angiotensin II type 1 receptor, can alter GPCR signaling, potentially affecting OR1L1. | ||||||
SCH 58261 | 160098-96-4 | sc-204272 sc-204272A | 10 mg 50 mg | $195.00 $825.00 | ||
Adenosine A2A receptor antagonist, can change adenosine signaling pathways and indirectly affect OR1L1. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
A P2 purinergic antagonist, can affect ATP-mediated GPCR signaling, potentially altering OR1L1 function. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
A potent P2X1 receptor antagonist, can modify GPCR signaling, which may influence OR1L1 activity. | ||||||